Overview
- Editors:
-
-
Ernest C. Borden
-
Center for Cancer Drug Discovery and Development, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, USA
Access this book
Other ways to access
Table of contents (13 chapters)
-
-
Perspective on the Clinical Disease
-
-
- Philip L. Bailin, Jon S. Meine, Christine Poblete-Lopez
Pages 3-38
-
-
- Hamed Daw, Thomas Olencki
Pages 73-92
-
Biological and Targeted Therapeutics
-
-
- Peter A. Cohen, Suyu Shu, James H. Finke
Pages 95-139
-
- Stanley P. L. Leong, Suyu Shu
Pages 141-156
-
- Paul B. Chapman, Jedd D. Wolchok
Pages 157-182
-
- James W. Mier, Michael B. Atkins
Pages 183-219
-
- Ronald M. Bukowski, Charles Tannenbaum
Pages 221-234
-
-
- Lawrence E. Flaherty, Philip Agop Philip
Pages 259-285
-
- Ruth Halaban, Maria C. von Willebrand
Pages 287-323
-
- Bela Anand-Apte, Paul L. Fox
Pages 325-360
-
-
Back Matter
Pages 379-389
About this book
Strategies of treatment involving therapeutic proteins, irnrnune immune cells, or cel lular protein targets are those of greatest potential for further reducing mortality from melanoma. Therapeutic proteins or cells may inhibit melanoma cell growth either by augmentation of immune cell function or by inhibition of angiogenesis. Cytokines and melanoma antigens may be used either in vivo as a vaccine to stimulate irnrnune immune cell cell function or ex vivo to stimulate or proliferate cells for infusion. Alternatively, alteration in melanoma cell growth can occur through inhibition of protein signal transduction pathways within melanoma cells or in the endothelial cells constituting the necessary angiogenic support for tumor growth. The great promise of these therapies and their cellular targets constitutes the basis for Melanoma: Biologically Targeted Therapeutics. THE CLINlCAL PROBLEM More than four million people will be diagnosed with melanoma in the first decade of the 21st century. Half of those who will die will be individuals who would otherwise have had a life expectancy of another 25 years or more. These individuals will die of systemic systernic metastases, which are present at the time of primary surgery. Despite use of sunscreens, incidence continues to increase in developed countries worldwide. To reduce mortality, there must continue to be a focus on prevention and earlier detection through public education. Early interventions are always preferable to treatment of disseminated metastatic disease.
Reviews
"Incredible detail to immunologic mechanisms is the strong point of the book. The bibliography at the end of each chapter is exhaustive, sometimes citing over 300 references.The pharmacokinetics of cytokines are meticulously discussed and diagrammed. Tables summarizing the results of clinical trials to date are peppered throughout the book. The authors are careful not to draw conclusions that do not have support from prospective randomized clinical trials. It is an excellent source to become familiar with current research and experimental protocols for advanced melanoma. Researchers and directors of melanoma clinics at tertiary care facilities will want to have this book as a resource."-Weighted Numerical Score: 100 - 5 Stars!-Doody's Health S ciences Book Review Journal
Editors and Affiliations
-
Center for Cancer Drug Discovery and Development, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, USA
Ernest C. Borden
